EUVIMEDEUVIMED entdecken
Systematische Übersicht

Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence

Sunil Dogra, Thammannagowda Prarthana, Gaikwad Sudharani, Seema Chhabra

Indian Journal of Dermatology, Venereology and Leprology · 13.10.2025 · 92 · 68-76

DOI: 10.25259/ijdvl_133_2025 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, online erschienen am 13.10.2025. Verfasst von Sunil Dogra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors, Skin Diseases, Dermatitis, Atopic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Upadacitinib, a second-generation oral Janus kinase (JAK) inhibitor, selectively targets the JAK 1 non-receptor protein kinase, effectively modulating downstream inflammatory pathways implicated in a range of dermatological diseases. Its JAK 1 selectivity mitigates unwanted side effects associated with broader JAK inhibition. FDA approval for moderate to severe atopic dermatitis (AD) in January 2022 marked a significant milestone, expanding treatment options in dermatology. Since then, upadacitinib has demonstrated efficacy in various dermatological disorders, contributing to improved patient outcomes. This review aims to spotlight its use in AD, as well as off-label indications in dermatology, its safety and efficacy profile, and pertinent information regarding side effects and contraindications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingJanus Kinase InhibitorsSkin DiseasesDermatitis, AtopicDermatologyDermatologic AgentsHumansTreatment Outcome

Stichwörter der Autor:innen

Atopic dermatitisJAK-STAT inhibitororal small moleculeupadacitinib

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Zitieren

APA

Dogra, S., Prarthana, T., Sudharani, G., & Chhabra, S. (2025). Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence. Indian Journal of Dermatology, Venereology and Leprology, 92, 68-76. https://doi.org/10.25259/ijdvl_133_2025

Vancouver

Dogra S, Prarthana T, Sudharani G, Chhabra S. Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence. Indian Journal of Dermatology, Venereology and Leprology. 2025;92:68-76. doi:10.25259/ijdvl_133_2025

BibTeX
@article{Dogra2025,
  author = {Dogra, Sunil and Prarthana, Thammannagowda and Sudharani, Gaikwad and Chhabra, Seema},
  title = {Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence},
  journal = {Indian Journal of Dermatology, Venereology and Leprology},
  year = {2025},
  volume = {92},
  pages = {68--76},
  doi = {10.25259/ijdvl_133_2025}
}
Kostenlos starten →